Castration-resistant prostate cancer: Where we stand in 2013 and what urologists should know

European Urology

Volumn 64, Issue 2, 2013, Pages 260-265

  Heidenreich, Axel ^a   Pfister, David ^a   Merseburger, Axel ^b   Bartsch, Georg ^c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; AFLIBERCEPT; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ARN 509; CABAZITAXEL; CABOZANTINIB; CORTICOSTEROID; DASATINIB; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; GALETERONE; GRANULOCYTE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; MITOXANTRONE; ODM 201; OGX 427; ORTERONEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIUM; RADIUM 223; SIPULEUCEL T; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CROSS RESISTANCE; DIARRHEA; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SOFT TISSUE METASTASIS; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

EID: 84879969831     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.05.021     Document Type: Editorial

References (33)

1. Heidenreich A, Bastian P, Bellmunt J, et al. Guidelines on prostate cancer. European Association of Urology Web site. http://www.uroweb.org/gls/pdf/ 09-Prostate-Cancer-LR.pdf.
2. J.S. De Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
3. J.S. De Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
4. K. Fizazi, H.I. Scher, and A. Molina Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983 992
5. Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol 2012;30(Suppl):LBA4512.
6. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
7. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
8. D.E. Rathkopf, M.R. Smith, and J.S. de Bone Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy [abstract 5] J Clin Oncol 31 Suppl 6 2013
9. I.F. Tannock, W.R. de, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
10. Oudard S, Kramer G, Creppy L, et al. Management of metastatic castration-resistant prostate cancer (mCRPC) after an initial good response to first-line docetaxel (D): a retrospective study on 270 patients (pts). Eur J Cancer. 2011;47(suppl 1):Abstract 7049.
11. Araujo JC, Trudel GC, Saad F, et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized phase III READY trial [abstract]. J Clin Oncol 2013;31(Suppl 6):LBA8.
12. I. Tannock, K. Fizazi, and F. Ivanov Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE) [abstract 13] J Clin Oncol 31 Suppl 6 2013
13. O. Caffo, G. Pappagallo, and S. Brugnara Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors Urology 79 2012 644 649
14. Y. Loriot, C. Massard, and M. Gross-Goupil The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer Eur J Cancer 46 2010 1770 1772
15. D. Pfister, D. Porres, C. Piper, A. Merseburger, T. Klotz, and A. Heidenreich Comparison of second-line treatments in patients with castration-resistant prostate cancer with PSA relapse after or during docetaxel chemotherapy [abstract 243] J Clin Oncol 30 Suppl 5 2012
16. O.B. Goodman, T.W. Flaig, and A. Molina Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) [abstract 14] J Clin Oncol 31 Suppl 6 2013
17. L. Albiges, E. Auclin, and B. Rousseau Is there a withdrawal syndrome with abiraterone acetate (AA) [abstract 89]? J Clin Oncol 31 Suppl 6 2013
18. R. Clayton, D.Y.C. Heng, and J.S.Y. Wu A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC) [abstract 113] J Clin Oncol 31 Suppl. 6 2013
19. H. Scher, K. Fizazi, and F. Saad Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor [abstract 6] J Clin Oncol 31 Suppl 6 2013
20. C. Sternberg, J. de Bono, and K.N. Chi Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial [abstract 16] J Clin Oncol 31 Suppl 6 2013
21. N.T. Fleming, H. Scher, and K. Fizazi Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: baseline characteristics and efficacy outcomes [abstract 20] J Clin Oncol 31 Suppl 6 2013
22. A. Heidenreich, H.J. Scholz, and S. Rogenhofer Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme Eur Urol 63 2013 977 982
23. A. Heidenreich, S. Bracarda, and M. Mason Cabazitaxel adverse events are manageable in senior adults with metastatic castration-resistant prostate cancer (mCRPC): results of the European Compassionate Use Programme Eur Urol Suppl 12 2013 e106 e107
24. A. Lipton Implications of bone metastases and the benefits of bone-targeted therapy Semin Oncol 37 Suppl 2 2010 S15 S29
25. K. Fizazi, M. Carducci, and M. Smith Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 2011 813 822
26. M.R. Smith, F. Saad, and R. Coleman Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial Lancet 379 2012 39 46
27. D.J.C.P. George, M.D. Michaelson, and H.J. Hammers Safety and activity of the investigational agent orteronel without prednisone in men with nonmetastatic castration-resistant prostate cancer and rising prostate specific antigen: updated results of a phase II study [abstract 4549] J Clin Oncol 30 Suppl 2012
28. Bruno RD, Gover TD, Burger AM, Brodie AM, Njar VC. 17alpha-Hydroxylase/ 17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Mol Cancer Ther. 2008 Sep;7(9):2828-36.
29. M.E.C.F. Taplin, J.P. Morrison, and R. Phili ARMORI1: safety of galeterone (TOK-001) in a phase I clinical trial in chemotherapy naïve patients with castration resistant prostate cancer [abstract CT-07] Cancer Res 72 Suppl 1 2012
30. D. Rathkopf, and H. Scher Androgen receptor antagonists in castration-resistant prostate cancer Cancer J 19 2013 43 49
31. J. Ischia, F. Saad, and M. Gleave The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer Curr Opinion Urol 23 2013 1 7
32. D.C. Smith, M.R. Smith, and C. Sweeney Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial J Clin Oncol 31 2013 412 419
33. J. Mezynski, C. Pezaro, and D. Bianchini Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 23 2012 2943 2947